Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Dec 2008

Di Nicolantonio Federica, Martini Miriam, Molinari Francesca, Sartore-Bianchi Andrea, Arena Sabrina, Saletti Piercarlo, De Dosso Sara, Mazzucchelli Luca, Frattini Milo, Siena Salvatore, Bardelli Alberto

Abstract excerpt

PURPOSE Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40% patients who are not responsive. The serine-threonine kinase BRAF is the principal effector of KRAS. We hypothesized that, in KR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HT29 Cells

Share to Niacinamide

Share to Panitumumab

Share to Phenylurea Compounds

Share to Sorafenib

Share to Switzerland

Source

Identifiers

PMID: 19001320
DOI: 10.1200/JCO.2008.18.0786

Genes

BRAF
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19001320-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.PMID 19001320Read ↗

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision OncologySemantic proximity Read ↗

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.Semantic proximity Read ↗

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.Semantic proximity Read ↗

Improvements in Clinical Outcomes for BRAFV600E -Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.Semantic proximity Read ↗

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.Semantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers.Semantic proximity Read ↗

New strategies for treatment of KRAS mutant metastatic colorectal cancer.Semantic proximity Read ↗

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.Semantic proximity Read ↗

Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.